Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection (20 ml: 0.5 g, Chemical Class 3.2).

The injectable fluoroquinolone is cleared for 11 indications covering mild to severe infections, including hospital- and community-acquired pneumonia, acute bacterial sinusitis, skin and urinary tract infections, chronic bacterial prostatitis, and post-exposure inhalational anthrax.

Key registration details • Marketing authorisation holder & manufacturer: Yaopharma Co., Ltd. • Drug approval number: Guo Yao Zhun Zi H20264412

Investment and market context • Cumulative R&D spending: RMB1.94 million (unaudited) through April 2026. • 2025 domestic sales of comparable levofloxacin injections reached RMB1.06 billion, according to IQVIA CHPA.

Management notes that market launch will broaden Fosun Pharma’s anti-infective pipeline, while actual sales will depend on demand, competitive landscape and channel penetration, and therefore remain uncertain.